EZH2 Abnormalities in Lymphoid Malignancies: Underlying Mechanisms and Therapeutic Implications

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2019 Nov 23

PMID 31752930

Citations 36

Authors

Boheng Li

Wee-Joo Chng

Affiliations

Soon will be listed here.

Abstract

EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which along with other PRC2 components mediates gene expression suppression via the methylation of Histone H3 at lysine 27. Recent studies have revealed a dichotomous role of EZH2 in physiology and in the pathogenesis of cancer. While it plays an essential role in the development of the lymphoid system, its deregulation, whether due to genetic or non-genetic causes, promotes B cell- and T cell-related lymphoma or leukemia. These findings triggered a boom in the development of therapeutic EZH2 inhibitors in recent years. Here, we discuss physiologic and pathogenic function of EZH2 in lymphoid context, various internal causes of EZH2 aberrance and how EZH2 modulates lymphomagenesis through epigenetic silencing, post-translational modifications (PTMs), orchestrating with surrounding tumor micro-environment and associating with RNA or viral partners. We also summarize different strategies to directly inhibit PRC2-EZH2 or to intervene EZH2 upstream signaling.

Citing Articles

Computational exploration in search for novel natural product-derived EZH2 inhibitors for advancing anti-cancer therapy.

Shyamal S Mol Divers. 2025; .

PMID: 39969739 DOI: 10.1007/s11030-025-11128-3.

An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models.

Zhang T, Beytullahoglu O, Tulaiha R, Luvisotto A, Szczepanski A, Tsuboyama N J Clin Invest. 2025; 135(2.

PMID: 39817454 PMC: 11735100. DOI: 10.1172/JCI179703.

A rare case of pediatric T-cell acute lymphoblastic leukemia with myeloid mimicry.

Ni W, Liu J, Deng K, Zeng Z, Kong Q, Weng X Discov Oncol. 2024; 15(1):691.

PMID: 39572436 PMC: 11582310. DOI: 10.1007/s12672-024-01600-1.

Epigenetic and Immune Profile Characteristics in Sinonasal Undifferentiated Carcinoma.

Ryu H, Lee C, Yoon S Cancer Med. 2024; 13(22):e70413.

PMID: 39565059 PMC: 11577451. DOI: 10.1002/cam4.70413.

EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.

Guo S, Tang Q, Gao X, Hu L, Hu K, Zhang H Acta Biochim Biophys Sin (Shanghai). 2024; 56(7):1055-1064.

PMID: 38804044 PMC: 11322866. DOI: 10.3724/abbs.2024077.

References

Dobenecker M, Park J, Marcello J, McCabe M, Gregory R, Knight S . Signaling function of PRC2 is essential for TCR-driven T cell responses. J Exp Med. 2018; 215(4):1101-1113. PMC: 5881460. DOI: 10.1084/jem.20170084. View

Souroullas G, Jeck W, Parker J, Simon J, Liu J, Paulk J . An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med. 2016; 22(6):632-40. PMC: 4899144. DOI: 10.1038/nm.4092. View

Sarmento O, Svingen P, Xiong Y, Sun Z, Bamidele A, Mathison A . The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). J Biol Chem. 2016; 292(2):706-722. PMC: 5241744. DOI: 10.1074/jbc.M116.749663. View

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

He S, Liu Y, Meng L, Sun H, Wang Y, Ji Y . Ezh2 phosphorylation state determines its capacity to maintain CD8 T memory precursors for antitumor immunity. Nat Commun. 2017; 8(1):2125. PMC: 5730609. DOI: 10.1038/s41467-017-02187-8. View

Baker T, Nerle S, Pritchard J, Zhao B, Rivera V, Garner A . Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015; 6(32):32646-55. PMC: 4741719. DOI: 10.18632/oncotarget.5066. View

Kim J, Lee Y, Lu X, Song B, Fong K, Cao Q . Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Rep. 2018; 25(10):2808-2820.e4. PMC: 6342284. DOI: 10.1016/j.celrep.2018.11.035. View

Su I, Basavaraj A, Krutchinsky A, Hobert O, Ullrich A, Chait B . Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol. 2002; 4(2):124-31. DOI: 10.1038/ni876. View

Lue J, Prabhu S, Liu Y, Gonzalez Y, Verma A, Mundi P . Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Clin Cancer Res. 2019; 25(17):5271-5283. PMC: 6726529. DOI: 10.1158/1078-0432.CCR-18-3989. View

10.

Wood C, Veenstra H, Khasnis S, Gunnell A, Webb H, Shannon-Lowe C . MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. Elife. 2016; 5. PMC: 5005034. DOI: 10.7554/eLife.18270. View

11.

Wang A, Pan D, Lee Y, Martinez G, Feng X, Dong C . Cutting edge: Smad2 and Smad4 regulate TGF-β-mediated Il9 gene expression via EZH2 displacement. J Immunol. 2013; 191(10):4908-12. PMC: 3842015. DOI: 10.4049/jimmunol.1300433. View

12.

Johnson D, Spitz G, Tharkar S, Quayle S, Shearstone J, Jones S . HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget. 2015; 6(7):4863-87. PMC: 4467121. DOI: 10.18632/oncotarget.3120. View

13.

Yi S, Sun J, Qiu L, Fu W, Wang A, Liu X . Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment. J Invest Dermatol. 2017; 138(5):1126-1136. DOI: 10.1016/j.jid.2017.10.036. View

14.

Gibaja V, Shen F, Harari J, Korn J, Ruddy D, Saenz-Vash V . Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene. 2015; 35(5):558-66. PMC: 4744243. DOI: 10.1038/onc.2015.114. View

15.

Xu L, Tang H, Wang K, Zheng Y, Feng J, Dong H . Pharmacological inhibition of EZH2 combined with DNA‑damaging agents interferes with the DNA damage response in MM cells. Mol Med Rep. 2019; 19(5):4249-4255. PMC: 6471932. DOI: 10.3892/mmr.2019.10075. View

16.

Gordon R, Ginalski K, Rudnicki W, Rychlewski L, Pankaskie M, Bujnicki J . Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem. 2003; 270(17):3507-17. DOI: 10.1046/j.1432-1033.2003.03726.x. View

17.

Chen W, Chen W, Jiang X, Jia X, Wang H, Zhang Q . HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer. World J Gastroenterol. 2017; 23(33):6100-6110. PMC: 5597501. DOI: 10.3748/wjg.v23.i33.6100. View

18.

Song Z, Wu W, Chen M, Cheng W, Yu J, Fang J . Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2. J Virol. 2018; 92(24). PMC: 6258931. DOI: 10.1128/JVI.00909-18. View

19.

Yan Y, Han J, Li Z, Yang H, Sui Y, Wang M . Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Mol Med Rep. 2016; 13(6):5125-31. PMC: 4878541. DOI: 10.3892/mmr.2016.5190. View

20.

Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B . Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012; 44(12):1316-20. DOI: 10.1038/ng.2469. View